These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Differential effects of a single dose of cyclophosphamide on T cell subsets of the thymus and spleen in mice: flow cytofluorometry analysis. Miyauchi A; Hiramine C; Tanaka S; Hojo K Tohoku J Exp Med; 1990 Oct; 162(2):147-67. PubMed ID: 2129070 [TBL] [Abstract][Full Text] [Related]
23. Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer. Berd D; Maguire HC; Mastrangelo MJ Cancer Res; 1984 Mar; 44(3):1275-80. PubMed ID: 6229330 [TBL] [Abstract][Full Text] [Related]
24. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophosphamide and granulocyte colony-stimulating factor. Condomines M; Quittet P; Lu ZY; Nadal L; Latry P; Lopez E; Baudard M; Requirand G; Duperray C; Schved JF; Rossi JF; Tarte K; Klein B J Immunol; 2006 Jun; 176(11):6631-9. PubMed ID: 16709821 [TBL] [Abstract][Full Text] [Related]
25. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. Smith D J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565 [TBL] [Abstract][Full Text] [Related]
26. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Takashima H; Smith DR; Fukaura H; Khoury SJ; Hafler DA; Weiner HL Clin Immunol Immunopathol; 1998 Jul; 88(1):28-34. PubMed ID: 9683547 [TBL] [Abstract][Full Text] [Related]
27. Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects. Mauch E; Kornhuber HH; Pfrommer U; Hähnel A; Laufen H; Krapf H Eur Arch Psychiatry Neurol Sci; 1989; 238(3):115-7. PubMed ID: 2721530 [TBL] [Abstract][Full Text] [Related]
28. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517 [TBL] [Abstract][Full Text] [Related]
29. T-cell subpopulations in blood and cerebrospinal fluid of multiple sclerosis patients: effect of cyclophosphamide. Brinkman CJ; Nillesen WM; Hommes OR Clin Immunol Immunopathol; 1983 Dec; 29(3):341-8. PubMed ID: 6605824 [TBL] [Abstract][Full Text] [Related]
30. Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients. Longbrake EE; Ramsbottom MJ; Cantoni C; Ghezzi L; Cross AH; Piccio L Mult Scler; 2016 Jul; 22(8):1061-1070. PubMed ID: 26459150 [TBL] [Abstract][Full Text] [Related]
31. Partial review of immunotherapeutic pharmacology in stem cell transplantation. Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081 [TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort. Portaccio E; Zipoli V; Siracusa G; Piacentini S; Sorbi S; Amato MP Mult Scler; 2003 Oct; 9(5):446-50. PubMed ID: 14582767 [TBL] [Abstract][Full Text] [Related]